Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo
Table 3
Risk factors of ocular sequelae among SJS/TEN survivors.
Sequelae
Univariate analysis
Multivariate analysis
Yes, n=26
No, n=45
OR
95% CI
P value
aOR
95% CI
P value
Age (years)
< 35 years, n (%)
21 (80.8)
27 (60.0)
2.80
[0.94-9.60]
0.0775
Sex
Female, n (%)
19 (73.1)
27 (60.0)
1.81
[0.65-5.43]
0.2692
Type of toxidermia
0.6929
SJS, n (%)
20 (76.9)
38 (84.4)
1
-
Overlap SJS/TEN, n (%)
2 (7.7)
3 (6.7)
1.27
[0.16-8.25]
TEN, n (%)
4 (15.4)
4 (8.9)
1.90
[0.41-8.83]
HIV serology, n=59
Negative, n (%)
12 (46.2)
21 (46.7)
0.78
[0.27-2.24]
0.6423
Ocular involvement at acute stage
0.0057
0.0005
None, n (%)
5 (19.2)
25 (55.6)
1
-
1
Mild, n (%)
7 (26.9)
13 (28.9)
2.69
[0.72-10.76]
3.55
[0.86-16.66]
0.0874
Moderate, n (%)
6 (23.1)
6 (13.3)
5.0
[1.15-23.54]
5.85
[1.23-31.81]
0.0303
Severe, n (%)
8 (30.7)
1 (2.2)
40.0
[5.66-835.63]
48.30
[6.25-1063.66]
0.0013
Used drugs, n=68
Sulfadoxine, n (%)
8 (30.7)
12 (26.7)
4.22
[1.17-17,59]
0.0331
5.95
[1.36-31.35]
0.0230
Sulfamethoxazole, n (%)
4 (15.4)
9 (20.0)
1.34
[0.30-5,61]
0.6814
Nevirapine, n (%)
9 (34.6)
20 (44.4)
1.49
[0.51-4,33]
0.4599
NSAIDs + analgesics, n (%)
3 (11.5)
3 (6.7)
2.107
[1.110−71-..]
0.9901
Time between ocular involvement and local ocular care, n=40
>7 days, n (%)
5 (19.2)
3 (6.7)
1.89
[0.39-10,50]
0.4333
Number of sessions of local ocular care/day, n=33
>1 day, n (%)
13 (50.0)
17 (37.8)
0.38
[0.02-4,42]
0.4522
Student test; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; OR: odds ratio; aOR: adjusted odds ratio; : HIV was known in 59 patients; : drug used found in 68 patients; : delay specified in 40 patients; : number of sessions specified 33 patients; NSAIDs: nonsteroidal anti-inflammatory drugs.
